The discipline pharma has is what makes AI safe to adopt.

Most conversations about AI in pharma start from fear: data leaking, black-box decisions, a compliance nightmare. That framing gets it backwards. Regulated industry already has the exact muscle AI adoption needs — validation, risk assessment, traceability, evidence. The question isn’t whether AI is safe for pharma; it’s whether anyone else is as well-equipped to do it properly.

Bounded, not black-box

Working inside a tool like Claude Code, the work is pigeonholed — scoped to a task, reviewable, and logged. That is the opposite of the data free-for-all people picture. It looks a lot like a controlled change: a defined scope, a record of what happened, and a human approving the result.

Agents and plug-ins as evidence generators

The interesting move is to make AI produce the documentation, not just the code. Agents and plug-ins can generate the logs, records, and evidence a regulated system needs — capturing what changed, why, and against which requirement — so the audit trail is a by-product of the work rather than an afterthought. That is the direction epiClavis ↗ is built to explore.

The commercial case

Point AI at the right places and the numbers move: faster delivery of bespoke internal software, lower vendor spend as in-house tools replace expensive licences, and services shaped around how staff actually work. Quality doesn’t drop — because the same validation discipline still governs the output.

A work in progress

This is niche, and deliberately so. It’s early, and it’s being built in the open. Parts will be released freely; the regulatory pieces are where the value — and the cost — sits. If your company is circling the same questions, that’s exactly the conversation I’m here for.